Skip to main content

Table 2 Multivariate analysis of factors associated with pCR

From: Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China

Parameters

OR (95% CI)

P value

Clinical N stage(≥ cN1 vs. cN0)

0.517(0.249 ~ 1.073)

0.077

HR status (negative vs. positive)

2.252(1.172 ~ 4.323)

0.015

HER2 status (3 + vs. 2 +)

4.576(1.682 ~ 12.449)

0.003

Cycles of targeted treatment (> 4 vs. 4)

1.841(0.925 ~ 3.664)

0.066

  1. Abbreviations: HR Hormone receptor, HER2 Human epidermal growth factor receptor 2, OR Odds ratio, CI Confidence interval